Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
Yokoyama Y, Nozawa E, Morita M, Ishikawa E, Mori T, Sakurai M, Kikuchi T, Matsuki E, Yamazaki R, Kataoka K, Jibiki A, Kawazoe H, Suzuki S, Nakamura T. Yokoyama Y, et al. Among authors: kawazoe h. J Clin Lab Anal. 2022 Aug;36(8):e24598. doi: 10.1002/jcla.24598. Epub 2022 Jul 12. J Clin Lab Anal. 2022. PMID: 35819095 Free PMC article.
Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study.
Kawazoe H, Murakami A, Yamashita M, Nishiyama K, Kobayashi-Taguchi K, Komatsu S, Aoki R, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y. Kawazoe H, et al. Clin Ther. 2018 Dec;40(12):2170-2179. doi: 10.1016/j.clinthera.2018.10.004. Epub 2018 Nov 2. Clin Ther. 2018. PMID: 30392814
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T. Ogiwara T, et al. Among authors: kawazoe h. Front Oncol. 2021 Nov 8;11:770268. doi: 10.3389/fonc.2021.770268. eCollection 2021. Front Oncol. 2021. PMID: 34820333 Free PMC article.
Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E, Yokoyama Y, Chishima H, Kuniyoshi O, Sato I, Nakaya N, Nakajima H, Kimura M, Hakamata J, Suehiro N, Nakada H, Ikemura S, Jibiki A, Kawazoe H, Muramatsu H, Suzuki S, Nakamura T. Ishikawa E, et al. Among authors: kawazoe h. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 May 30;1199:123245. doi: 10.1016/j.jchromb.2022.123245. Epub 2022 Apr 4. J Chromatogr B Analyt Technol Biomed Life Sci. 2022. PMID: 35436724 Free article.
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E, Yokoyama Y, Chishima H, Kasai H, Kuniyoshi O, Kimura M, Hakamata J, Nakada H, Suehiro N, Nakaya N, Nakajima H, Ikemura S, Kawada I, Yasuda H, Terai H, Jibiki A, Kawazoe H, Soejima K, Muramatsu H, Suzuki S, Nakamura T. Ishikawa E, et al. Among authors: kawazoe h. Invest New Drugs. 2023 Feb;41(1):122-133. doi: 10.1007/s10637-023-01328-9. Epub 2023 Jan 13. Invest New Drugs. 2023. PMID: 36637703 Free PMC article.
106 results